Reimbursement stimulates South Korea's contrast media
This article was originally published in Clinica
Demand for radioactive contrast media in South Korea has been increasing rapidly since the inclusion of CT and MRI scans in the reimbursement system at the end of 1995. South Korea's contrast media market is expected to total around Won 150,000 million ($193 million) by the end of the decade, reports Pharma Koreana.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.